Drugmaker Bristol Myers Squibb to boost neuroscience portfolio with acquisition of Karuna Therapeutics in $14b deal
In a $14 billion transaction, pharmaceutical giant Bristol Myers Squibb will purchase biopharmaceutical startup Karuna Therapeutics, which has created a novel antipsychotic. Karuna and Bristol

